Glenmark, Bausch Health partner to commercialise RYALTRIS nasal spray in Canada
RYALTRIS is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Govt of India gives ‘India Pharma Innovation of the Year’ Award to Glenmark
The Award recognises Glenmark’s patents and commercialised innovations over the last three years
Glenmark launches Remogliflozin + Vildagliptin FDC in India to treat Type 2 diabetes
The FDC will be marketed under two brand names, Remo V and Remozen V, priced at Rs 14 per tab and Rs 28 per day cost of therapy
Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules
It is the generic version of Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim
Dr Reddy’s to acquire select anti-allergy brands from Glenmark in Russia and other CIS countries
The acquired brands represent two types of products, mometasone mono product and combination of mometasone with azelastine.
Glenmark appoints Dipankar Bhattacharjee to its Board of Directors
Bhattacharjee was previously President & CEO – Global Generic Medicines of Teva Pharmaceutical Industries
Glenmark to launch FabiFlu (400 mg) for COVID-19 treatment
With the new 400 mg version, patients need to consume nine tablets on Day 1, and thereafter two tablets twice a day from Day 2…
DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities
As per statement by the Glenmark and media reports, the DCGI had accelerated the process for clinical trials and reviews…
Glenmark launches hypertension awareness symbol, endorsed by API and HSI
Pledges on-ground screening of 5 million people for high BP in India
Glenmark Pharmaceuticals has launched the world’s first…
Glenmark Pharma cuts price of COVID-19 drug by 27 pc to Rs 75/tablet
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet